Assessment of 1p/19q deletions by fluorescence in situ hybridization in gliomas.

Cancer Genet Cytogenet

Genzyme Genetics, 521 West 57th Street, New York, NY 10025, USA.

Published: July 2008

This study assessed the efficacy of FISH for detecting 1p/19q deletion in gliomas on 77 paraffin-embedded tissue samples, of which 42 cases (55%) were positive for 1p/19q codeletion; 7 of the 42 had a previous history of glioma. In one case, analysis failed. The remaining 34 cases were negative; of these, three had a previous history of glioma and one had the reverse 1q/19p deletion. A majority of the 10 recurrent gliomas had progressed, and 70% had a 1p/19q deletion. The signal pattern in a majority of 1p/19q codeletion cases was a single red marker signal and two green reference signals (1R2G) for both probe sets. One case had a different signal pattern for chromosomes 1 and 19 (1R2G and 2R4G), as seen in polysomy cells. Three cases had two target and four control signals (2R4G), as seen in tetraploid cells. Eleven had complex signal patterns seen in diploid and polyploid cells (1R2G/

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergencyto.2008.03.009DOI Listing

Publication Analysis

Top Keywords

1p/19q deletion
8
1p/19q codeletion
8
previous history
8
history glioma
8
signal pattern
8
assessment 1p/19q
4
1p/19q deletions
4
deletions fluorescence
4
fluorescence situ
4
situ hybridization
4

Similar Publications

Article Synopsis
  • IDH-mutant gliomas are the most common malignant brain tumors in young adults, causing significant challenges for patients, including cognitive deficits and high mortality due to tumor progression.
  • Current treatments like surgery, radiation, and chemotherapy enhance survival but can have negative impacts on cognitive function and quality of life.
  • The recent FDA approval of vorasidenib, a drug targeting mutant IDH1/2 proteins, represents a promising new approach, with ongoing trials exploring its use alongside other therapies for better patient outcomes.
View Article and Find Full Text PDF

The mesenchymal transformations of infiltrating gliomas are uncommon events. This is particularly true of IDH-mutant astrocytomas and oligodendrogliomas, in which mesenchymal transformation is exceedingly rare. oligosarcoma is a newly recognized methylation class (MC) that represents transformed 1p/19q co-deleted oligodendrogliomas, but recent studies indicate it may be non-specific.

View Article and Find Full Text PDF

Isocitrate dehydrogenase (IDH) mutant gliomas are classified as astrocytoma or oligodendroglioma based on the recent application of mutation, mutation, and 1p/19q co-deletion. Astrocytomas classically show and mutations, whereas oligodendrogliomas are defined by 1p/19q co-deletion. However, there are reports of gliomas that harbor both astrocytoma and oligodendroglioma morphologically and molecularly.

View Article and Find Full Text PDF

Gliomas are a heterogeneous group of brain tumors, among which the most aggressive subtype is glioblastoma, accounting for 60% of cases in adults. Available systemic treatment options are few and ineffective, so new approaches to therapies for glioblastoma are in high demand. In total, 131 patients with diffuse glioma were studied.

View Article and Find Full Text PDF
Article Synopsis
  • Glioblastoma (GBM) is a highly aggressive brain cancer with few treatment options, and the study focuses on exploring extracellular vesicles (EVs) from GBM cells as potential diagnostic biomarkers.
  • * The research utilized tumor explants from GBM patients to preserve tumor characteristics and successfully isolated EVs, analyzing their surface markers through advanced techniques.
  • * Results showed unique surface biomarker expression patterns in GBM-derived EVs that could differentiate them from healthy controls, indicating their potential role in noninvasive diagnosis and understanding of GBM progression.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!